Physician profile
Mansur Khalid Pathan
NPI 1144615220
$767.08
in general payments reported to CMS, 2019-2025
14 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.99 · 2020: $94.49 · 2021: $424 · 2023: $23.10 · 2024: $14.69 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $35.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.62 |
| Education | $35.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $138.86 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $111.12 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $85.44 | 2020-2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $78.77 | 2025 | |
| Akebia Therapeutics INC | $71.28 | 2020-2021 | |
| Fresenius USA Marketing, INC. | $66.38 | 2020-2021 | |
| Daiichi Sankyo INC. | $43.91 | 2021 | |
| Calliditas Therapeutics US INC. | $34.77 | 2025 | Tarpeyo |
| Amgen INC. | $29.14 | 2024-2025 | Tavneos |
| Apellis Pharmaceuticals, INC. | $27.84 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $24.84 | 2021 | |
| Nxstage Medical, INC. | $18.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $16.89 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansur Pathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.